One World Trade Center
22nd Floor
New York, NY 10007
United States
212 332 3241
https://www.axsome.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 569
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Herriot Tabuteau M.D. | Founder, Chairman, CEO & President | 1.4M | N/A | 1968 |
Mr. Nick Pizzie CPA, M.B.A. | Chief Financial Officer | 765.48k | N/A | 1975 |
Mr. Mark L. Jacobson M.A. | Chief Operating Officer | 835.84k | N/A | 1983 |
Mr. Hunter Murdock Esq. | General Counsel & Secretary | 757.31k | N/A | 1980 |
Ms. Lori Englebert M.B.A. | Executive Vice President of Product Strategy | N/A | N/A | 1978 |
Mr. Ari Maizel | Executive VP & Head of Commercial | N/A | N/A | N/A |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Axsome Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 8; Compensation: 8.